CE / CME
In this module, 2 world-renowned experts review promising and practice-changing data in studies of hematologic malignancies presented at the 2026 ASCO and EHA conferences. This activity features expert insights and clinical implications of new, novel and emerging strategies in chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma including latest data from ASC4FIRST (asciminib), MAXILUS (luspatercept), EPO-PRETAR (erythropoietin stimulating agents), OPTI-AML (azacitidine/venetoclax optimization), KOMET-007 (ziftomenib), AJX-101 (AJ1-11095), SENTRY (selinexor/ruxolitinib), frontMIND (tafasitamab/lenalidomide + R-CHOP), BRUIN CLL-322 (pirtobrutinib + venetoclax/rituximab), BRUIN CLL-313/314 (pirtobrutinib), CLL14 (venetoclax/obinutuzumab), CaDAnCe-101 (tacabrutideg), and a sonrotoclax plus zanubrutinib trial.
ABIM MOC: maximum of 1.00 Medical Knowledge MOC point
Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™
Released: August 31, 2026
Expiration: February 28, 2027
Share
Provided by Clinical Care Options, LLC dba Decera Clinical Education
This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.
Incyte Corporation
Lilly
Novartis Pharmaceuticals Corporation
This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies.
This activity aims to improve learners’ knowledge, confidence, and competence at applying recent, practice-changing findings to the optimal management of patients with hematologic malignancies.
Upon completion of this activity, participants should be able to:
Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes
Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies
Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice
Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary AuthorMatthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.
Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Cullinan, Daiichi Sankyo, Geron, Johnson & Johnson, Kura/Kirin Kyowa, Menarini/Stemline, Novartis, Servier, Takeda.
The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 31, 2026, through February 28, 2027:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
EBAH-CME Accreditation

The program of Decoding Discoveries in Hematologic Malignancies—Decera Clinical Education's Independent Highlights of the 2026 ASCO and EHA Conferences has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH) CME Unit. The EBAH-CME Unit has approved this educational activity for a maximum of 1.0 CME credit. Each physician should only claim credits for time that they actually spent in the educational activity.
All participants may print a European Board for Accreditation in Hematology (EBAH) CME certificate indicating EBAH-CME Credit Points awarded, directly from the system on the CME section of the EBAH website at (www.ebah.org).
How to collect your EBAH-CME credit points:
Within the EBAH-CME system, you can:
CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.